SCHEMBL23960541

SCHEMBL23960541

CC(C)(C)OC(=O)NCc1ccc(OC2CNCC(c3ccccc3)C2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.44
HDAC1 Q13547 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HSD17B10 Q99714 1/20 0.40
MASP2 O00187 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM1A O60341 1/20 0.39
MAOB P27338 1/20 0.39
JAK3 P52333 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
TACR1 P25103 1/20 0.38
KCNH2 Q12809 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MAOA P21397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30151669 0.89 BRD4 (0.41) NAMPTHDAC1KDM1AMAOBJAK3
SCHEMBL26078682 0.89 BRD4 (0.41) NAMPTHDAC1KDM1AMAOBJAK3
SCHEMBL23932419 0.87 HSD17B10 (0.46) HSD17B10JAK3KCNH2FFAR4
SCHEMBL23960607 0.81 NAMPT (0.42) NAMPTHDAC1L3MBTL1HSD17B10KMT2A
SCHEMBL30636567 0.81 NAMPT (0.42) NAMPTHDAC1L3MBTL1HSD17B10KMT2A
SCHEMBL30151664 0.81 NAMPT (0.42) NAMPTHDAC1L3MBTL1HSD17B10KMT2A
SCHEMBL23960627 0.80 L3MBTL1 (0.41) NAMPTHDAC1L3MBTL1CA12CA1
SCHEMBL10233014 0.77 ALDH1A1 (0.52) NAMPTHDAC1L3MBTL1NPC1RAB9A
SCHEMBL30151671 0.76 BRD4 (0.39) NAMPTL3MBTL1HSD17B10
SCHEMBL23960608 0.76 BRD4 (0.39) NAMPTL3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310445-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. 2023-10-05 US disclosed
US-20230310445-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. 2023-10-05 US disclosed
US-20230310445-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. 2023-10-05 US disclosed
EP-4138824-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS Anovia Biosciences, Inc. (US) 2023-03-01 EP disclosed
WO-2021216592-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310445-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS LOX, LOXL1, LOXL2 NAMPT 865/4885HDAC1 471/4885L3MBTL1 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.